Lung

• (122-18) Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (Phase 2 clinical trial, appropriate for patients with non-small cell lung cancer.)

• (131-17) A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers (Phase 1 clinical trial, appropriate for patients with solid tumors.)

• (134-17) A Phase IIa trial of sEphB4-HSA in combination with Anti PD-1 Antibody (Pembrolizumab, MK-3475) in patients with non-small cell lung and head/neck cancer (Phase 2 clinical trial, appropriate for patients with lung, head or neck cancer.)

• (155-17) 0C 17-1: Phase 1 Multi-center Study of the Safety Pharmacokinetics and Preliminary Efficacy of CBT-101 in Subjects with Advanced Solid Tumors and C-Met Dysregulation (Phase 1 clinical trial, appropriate for patients with advanced solid malignancies.)

• (157-17) FID-007 in Treating Participants With Advanced Solid Tumors (Phase 1 clinical trial, appropriate for patients with advanced solid malignancies.)

• (167-17) Caris ctDNA Validation Project (Research study, appropriate for patients with all solid tumors.)

• (208-17) A multicenter, open-label, phase 1b/2 study to evaluate safety and efficacy of avelumab (MSB0010718C) in combination with chemotherapy with or without other anti-cancer immunotherapies as first-line treatment in patients with advanced malignancies (Phase 1b/2 clinical trial, appropriate for patients with bladder and lung cancers.)

• (211-17) Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients (Phase 1 clinical trial, appropriate for patients with advanced solid tumors.)

• (214-17) A Phase 1/2 First-in-human Study of BMS-986258 Alone and in Combination with Nivolumab in Advanced Malignant Tumors (Phase 1/2 clinical trial, appropriate for patients with advanced malignant tumors.)

Certain clinical trials may not be listed on ClinicalTrials.gov. To learn more about these or other clinical trials, please call 949-764-5543 or contact us online.